Ulocuplumab
Based on 1 publication(s) in Google Scholar
Ulocuplumab (Anti-Human CXCR4 Recombinant Antibody/BMS-936564/MDX1338) is a fully human IgG4 anti-CXCR4 antibody. Ulocuplumab induces apoptosis and inhibits CXCL12 mediated CXCR4 activation-migration of chronic lymphocytic leukemia (CLL). Ulocuplumab exhibits antitumor activity in established tumors including acute myeloid leukemia (AML), non-Hodgkin lymphoma (NHL), and multiple myeloma xenograft models.
For research use only. We do not sell to patients.
- Purity: 99.90%
- CAS No.: 1375830-34-4
- Molecular Weight:144.84 kDa
-
Storage:
Please store the product under the recommended conditions in the Certificate of Analysis.
Publications Citing Use of MedChemExpress (MCE) Ulocuplumab
More
Biological Activity
Human IgG4 kappa
Human
|
CXCR4 |
Ulocuplumab (0-100 μM; 48 h) lacks antibody dependent cellular cytotoxicity (ADCC) or complement (CDC) activity, but also induces apoptosis mediated by CXCR4 binding in Ramos cells and CLL/cancer cell lines, also shows pro-apoptotic in primary leukemia cells from CLL patients[1].
Ulocuplumab (0.2 μM and 2 μM; 15 s) inhibits F-actin polymerization and reduces the peak response to CXCL12, and also (20 nM-2 μM; 1 h) inhibits cell migration[1].
Ulocuplumab (200 nM; 6 h) leads to induction of programmed cell death (PCD) is caspase independent[1].
Ulocuplumab (10 μg/mL; 4 h) induces cell death via production of reactive oxygen species (ROS) in CLL cells[1].
Ulocuplumab inhibits CXCL12-induced calcium flux with an EC50 value of 10 nM in Ramos[2].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Cell Line:Ramos cells and primary leukemia cells (from CLL patients)
-
Concentration:0-100 μM
-
Incubation Time:48 hours
-
Result:Induced apoptosis in Ramos cells with an IC50 value of 1.9 nM and showed pro-apoptotic with an IC50 value of 12.43 nM in primary leukemia cells from CLL patients.
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:Severe combined immunodeficient (SCID) mice of AML model (MOLP-8 cells)[1]
-
Dosage:3-30 mg/kg
-
Administration:Intraperitoneal injection; every 3-4 days for 5 doses; last for 65 days
-
Result:Significantly delayed mean tumor growth by 66% and 56% when compared with isotype control on day 25.
| NCT Number | Sponsor | Condition | Start Date |
Phase
|
|---|---|---|---|---|
| NCT01329991 | Plexxikon| | 2011-05 | PHASE1 |
Unconjugated
The product can be reconstituted/diluted with sterile PBS or saline.
-
Human IgG4 kappa
ELISA, FACS, Functional assay
-
Immobilized Human CXCR4/CD184 (Full Length) Protein-VLP can bind Ulocuplumab. The EC50 for this effect is 36.64 ng/mL. -
Flow cytometric analysis of 1.5×106 THP-1 cells with Ulocuplumab (HY-P99272, red). Cells were fixed with 4% paraformaldehyde and permeabilised with 90% methanol. Then stained with the primary antibody at 1/200 dilution for an hour at 4℃. Alexa Goat Anti-Human IgG H&L (AF488) (HY-P83776) was used as the secondary antibody at 1/1,000 dilution for 30 minutes at 4℃. Human IgG4 (S228P) kappa Isotype Control (HY-P99003, blue) was used as the isotype control, cells without incubation with primary antibody were used as the unlabeled control (black).
Chemical Information
-
CAS No. 1375830-34-4
-
Appearance Liquid
-
Molecular Weight 144.84 kDa
-
Color Colorless to light yellow
-
SMILES
[Ulocuplumab]
-
Synonyms
BMS 936564; MDX 1338; Anti-Human CXCR4 Recombinant Antibody
-
Shipping
Shipping with dry ice.
-
Formulation
Please refer to the lot-specific COA for specific buffer information.
-
Storage
Please store the product under the recommended conditions in the Certificate of Analysis.
Publications (1)
-
Journal Impact Factor
-
Most Recent
-
Signal Transduct Target Ther
Targeting TRPV6/CXCR4 complexes prevents castration-resistant prostate cancer metastasis to the bone. [Abstract]2025 Sep 5;10(1):287. PMID: 40908300
Purity & Documentation
-
Data Sheet (262 KB)
-
SDS (252 KB)
- English - EN (252 KB)
- Français - FR (252 KB)
- Deutsch - DE (252 KB)
- Norwegian - NO (252 KB)
- Español - ES (252 KB)
- Swedish - SV (252 KB)
- Italian - IT (252 KB)
- Korean - KR (252 KB)
- Portuguese - PT (252 KB)
-
Inhibitory Antibodies User Guide (603 KB)
References
[1]. Kashyap MK, et al. Ulocuplumab (BMS-936564 / MDX1338): a fully human anti-CXCR4 antibody induces cell death in chronic lymphocytic leukemia mediated through a reactive oxygen species-dependent pathway. Oncotarget. 2016 Jan 19;7(3):2809-22. [Content Brief]
[2]. Kuhne MR, et al. BMS-936564/MDX-1338: a fully human anti-CXCR4 antibody induces apoptosis in vitro and shows antitumor activity in vivo in hematologic malignancies. Clin Cancer Res. 2013 Jan 15;19(2):357-66. [Content Brief]
Calculators
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)